5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Evan Roberts, President of Provider Solutions at Phreesia, Inc. (NASDAQ:PHR), a healthcare software company with a market capitalization of $1.4 billion and "GOOD" financial health rating according to InvestingPro, sold 1,888 shares of common stock on October 17, 2025. The shares were sold at a weighted average price of $22.3612, for a total transaction value of $42,217. Prices for the sales ranged from $22.195 to $22.66 per share. The stock currently trades at $23.11, slightly below its InvestingPro Fair Value, with analysts maintaining a strong buy consensus.
Following the transaction, Roberts directly owns 724,949 shares of Phreesia, Inc. The sale was executed to cover tax withholding obligations related to the settlement of performance-based restricted stock units, according to a footnote in the SEC filing. The company maintains strong liquidity with a current ratio of 2.12, and while currently unprofitable, analysts expect positive earnings this year. Discover more insights about PHR and 1,400+ other stocks with InvestingPro’s comprehensive research reports.
In other recent news, Phreesia Inc. announced its acquisition of AccessOne for $160 million, marking the largest acquisition in the company’s history. This strategic move is expected to add approximately $35 million in annual revenue and $11 million in EBITDA once the deal closes in the second half of fiscal year 2026. Meanwhile, Phreesia’s latest revenue and adjusted EBITDA results surpassed consensus expectations, although the company maintained its fiscal year 2026 revenue guidance.
Analyst firms have responded to these developments with various updates. Truist Securities raised its fiscal year 2026 and 2027 EBITDA estimates for Phreesia to $90 million and $110 million, respectively, and increased its stock price target to $36, while maintaining a Sell rating. Citizens JMP raised its price target to $34, maintaining a Market Outperform rating, influenced by the acquisition news. Raymond James also increased its price target to $33, retaining an Outperform rating. Additionally, DA Davidson assumed coverage with a Buy rating and set a price target of $33.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.